New Insulin Pump System Shows Promise for Better Blood Sugar Control in Young People with Type 1 Diabetes

Researchers in Greece recruited 28 children and adolescents with Type 1 diabetes to test the Medtrum A8+ TouchCare Nano system. This is an automated insulin delivery system that combines a continuous glucose monitor with an insulin pump and uses an algorithm to automatically adjust insulin doses.

The study compared how well participants managed their diabetes before and after starting the new system. Researchers measured blood sugar control and asked participants about their satisfaction with the device and how it worked for them.

After using the A8+ TouchCare Nano system, participants showed improvements across multiple measures of glucose management. These included better time spent in healthy blood sugar ranges, lower HbA1c levels (a measure of average blood sugar over time), and fewer episodes of very high blood glucose.

The improvements were similar whether participants used the closed-loop (fully automated) or open-loop (semi-automated) features of the system, and results held steady across different age groups.

Participants reported higher overall satisfaction with their diabetes management when using the system. They particularly appreciated two features: the predictive low glucose suspend function, which alerts and stops insulin delivery before blood sugar drops too low, and the Auto Meal Handling feature, which automatically adjusts for carbohydrates without requiring manual counting.

While this was a small study, the consistent positive feedback about ease of use and peace of mind suggests these automated features may reduce some of the daily burden of managing Type 1 diabetes.

This research adds to growing evidence that automated insulin delivery systems can improve both blood sugar control and quality of life for young people with Type 1 diabetes. However, this was a small study in Greece, so larger and more diverse studies would help confirm these results apply more broadly.

Anyone considering a new insulin pump or automated system should discuss options with their healthcare team, as the right choice depends on individual needs, preferences, and access to technology.

Source: World journal of clinical pediatrics. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.